Affiliation:
1. BluePearl Veterinary Specialists Spring Texas USA
Abstract
AbstractBackgroundDexmedetomidine (Dexmedetomidine hydrochloride‐Dexdomitor; Zoetis) is the preferred sedative used for canine intradermal allergen testing (IDT) in the United States. Alfaxalone (Alfaxan Multidose; Jurox Animal Health) is a neuroactive steroid, and its effect on sedation and allergen reactivity scores is unknown.Hypothesis/ObjectivesWe hypothesised that alfaxalone would produce an adequate level of sedation with fewer cardiovascular adverse effects and would not affect allergen reactivity scores or histamine wheal size compared to dexmedetomidine.Materials and MethodsTwenty client‐owned dogs were included in two groups: 10 atopic and 10 nonatopic. In a randomised, controlled, blinded, cross‐over design all dogs underwent two modified IDT, 1–4 weeks apart, using intravenous dexmedetomidine (2.87–5.22 μg/kg) or alfaxalone (1.8–2.4 mg/kg). Anaesthetic parameters and sedation level were recorded over 25 min using a validated canine sedation scale described by Grint et al. (Small Anim Pract, 2009, 50, 62). Simultaneously, both objective and subjective reactivity scores were measured in technical triplicates at 10, 15 and 20 min. The modified IDT included eight allergens, histamine‐positive and saline‐negative controls.ResultsAlfaxalone produced a significantly higher sedation score across all time points (p < 0.05). All objective scores were significantly correlated to the corresponding subjective scores (Spearman R = 0.859, p < 0.0001). Sedative used did not significantly affect subjective allergen scores for nine atopic dogs (p > 0.05, 15 min). Sedative used did not affect the diameter of objective scores for individual allergens and histamine wheals (p > 0.05, 15 min).Conclusions and Clinical RelevanceIntravascular alfaxalone is an alternative sedative for IDT in dogs. Alfaxalone may be preferred to dexmedetomidine in some clinical scenarios as a result of having fewer cardiovascular adverse effects.